• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨转移非小细胞肺癌患者骨骼相关事件的预测因素。

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

机构信息

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, Republic of Korea.

出版信息

Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.

DOI:10.1016/j.lungcan.2010.04.003
PMID:20598769
Abstract

BACKGROUND

Skeletal-related events (SREs) cause significant pain and morbidity to many non-small cell lung cancer (NSCLC) patients. We try to evaluate the predictive factor of SREs in NSCLC patients with bone metastases.

PATIENTS AND METHODS

We retrospectively examined the medical charts of 273 patients diagnosed with bone metastases secondary to NSCLC. The predictive factor of SREs was analyzed using the first-event analyses and a survival-adjusted multiple-event analysis.

RESULTS

Out of 273 patients with bone metastases, 171 (62.6%) had at least one SRE and 46 of these experienced multiple SREs. In the first-event analyses, a larger proportion of ever-smokers have experienced the SRE compared with never-smokers (odds ratio, 2.80; 95% CI, 1.32-6.00). In addition, ever-smokers (hazard ratio [HR], 1.75; 95% CI, 1.05-2.92), patients without history of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy (HR, 2.12; 95% CI, 1.49-3.00) and patients with histology of nonadenocarcinoma (HR, 1.59; 95% CI, 1.14-2.22) had a shorter median time from bone metastasis to first SRE. In a survival-adjusted multiple-event analysis, clinical characteristics such as ever-smoking, nonadenocarcinoma, poor performance status (ECOG≥2), and no history of EGFR TKI therapy were independent risk factor of development of SRE throughout the course of disease.

CONCLUSION

Our data indicate that patients with characteristics such as ever-smoking, nonadenocarcinoma, poor performance status, and no history of treatment with EGFR TKI are more likely to have SRE, so more vigilant surveillance and prevention should be considered to these patients.

摘要

背景

骨骼相关事件(SREs)会给许多非小细胞肺癌(NSCLC)患者带来严重的疼痛和发病。我们试图评估有骨转移的 NSCLC 患者发生 SRE 的预测因素。

患者和方法

我们回顾性检查了 273 例诊断为 NSCLC 继发骨转移的患者的病历。使用首次事件分析和生存调整的多事件分析来分析 SRE 的预测因素。

结果

在 273 例有骨转移的患者中,171 例(62.6%)至少发生了一次 SRE,其中 46 例发生了多次 SRE。在首次事件分析中,与从不吸烟者相比,曾经吸烟者发生 SRE 的比例更高(比值比,2.80;95%可信区间,1.32-6.00)。此外,曾经吸烟者(风险比[HR],1.75;95%可信区间,1.05-2.92)、无表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗史的患者(HR,2.12;95%可信区间,1.49-3.00)和非腺癌组织学的患者(HR,1.59;95%可信区间,1.14-2.22)从骨转移到首次 SRE 的中位时间更短。在生存调整的多事件分析中,临床特征如曾经吸烟、非腺癌、较差的表现状态(ECOG≥2)和无 EGFR TKI 治疗史是疾病过程中发生 SRE 的独立危险因素。

结论

我们的数据表明,具有曾经吸烟、非腺癌、较差的表现状态和无 EGFR TKI 治疗史等特征的患者更有可能发生 SRE,因此应考虑对这些患者进行更严密的监测和预防。

相似文献

1
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.骨转移非小细胞肺癌患者骨骼相关事件的预测因素。
Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.
2
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.接受化疗的非小细胞肺癌患者发生骨相关事件的危险因素。
Lung Cancer. 2009 Aug;65(2):219-22. doi: 10.1016/j.lungcan.2008.10.026. Epub 2008 Dec 10.
3
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.在接受吉非替尼治疗既往治疗过的晚期或转移性非小细胞肺癌患者中,皮疹和支气管肺泡组织学与临床获益相关。
Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14.
4
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.初诊时发生骨转移的非小细胞肺癌的预后因素。
Lung Cancer. 2012 Sep;77(3):572-7. doi: 10.1016/j.lungcan.2012.05.094. Epub 2012 Jun 4.
5
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.质谱分析用于对接受表皮生长因子受体酪氨酸激酶抑制剂治疗后的非小细胞肺癌患者的临床结局进行分类:一项多队列跨机构研究。
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195.
6
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.在非小细胞肺癌骨转移病灶疾病进展后,行放疗的同时持续给予 EGFR-TKIs 治疗。
Anticancer Res. 2011 Dec;31(12):4519-23.
7
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)对具有敏感EGFR突变或其他EGFR TKI良好反应预测因素的非小细胞肺癌患者的软脑膜转移有效。
Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6.
8
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.唑来膦酸和锶-89 治疗非小细胞肺癌无症状骨转移患者的临床意义。
Clin Lung Cancer. 2013 May;14(3):254-60. doi: 10.1016/j.cllc.2012.09.001. Epub 2012 Oct 25.
9
Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.非小细胞肺癌骨转移患者发生骨相关事件(SREs)的危险因素及影响无SRE生存的因素。
Tumour Biol. 2016 Jan;37(1):1131-40. doi: 10.1007/s13277-015-3907-z. Epub 2015 Aug 15.
10
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.在接受 EGFR-TKI 治疗的日本 NSCLC 患者中,获得性耐药相关分子的预后价值。
Anticancer Res. 2012 Sep;32(9):3785-90.

引用本文的文献

1
Efficacy of Immunotherapy in Patients With Bone Metastases From Driver Gene-Negative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.免疫疗法对驱动基因阴性的非小细胞肺癌骨转移患者的疗效:一项随机对照试验的系统评价和荟萃分析
Clin Med Insights Oncol. 2025 May 26;19:11795549251338144. doi: 10.1177/11795549251338144. eCollection 2025.
2
Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting.自噬在骨转移中的双重作用:机制洞察与治疗靶点
Am J Clin Exp Urol. 2025 Apr 25;13(2):92-117. doi: 10.62347/QCPV6064. eCollection 2025.
3
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.
创新全身治疗联合放疗用于骨转移的疗效:欧洲骨转移研究组(GEMO)的最新进展
Cancer Metastasis Rev. 2025 Jan 29;44(1):28. doi: 10.1007/s10555-024-10236-0.
4
Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with -mutated non-small-cell lung cancer: a retrospective, multicenter cohort study.股骨骨转移是表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗的伴有突变的非小细胞肺癌患者的不良预后因素:一项回顾性多中心队列研究。
Ther Adv Med Oncol. 2024 Dec 20;16:17588359241303090. doi: 10.1177/17588359241303090. eCollection 2024.
5
Worldwide research trends on bone metastases of lung cancer: a bibliometric analysis.肺癌骨转移的全球研究趋势:一项文献计量分析。
Front Oncol. 2024 Oct 25;14:1429194. doi: 10.3389/fonc.2024.1429194. eCollection 2024.
6
Metastatic pattern and prognosis in patients with lung adenosquamous carcinoma: A surveillance, epidemiology, and end results-based population study.肺腺鳞癌患者的转移模式与预后:一项基于监测、流行病学及最终结果的人群研究。
Heliyon. 2024 May 6;10(9):e30641. doi: 10.1016/j.heliyon.2024.e30641. eCollection 2024 May 15.
7
Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets.非小细胞肺癌中的骨转移:基因组特征及潜在靶点探索
Ther Adv Med Oncol. 2024 Mar 19;16:17588359241239293. doi: 10.1177/17588359241239293. eCollection 2024.
8
Metastatic Lung Adenocarcinoma: A Case of Unusual Presentation With a Skull Mass.转移性肺腺癌:一例以颅骨肿块为不寻常表现的病例。
Cureus. 2023 Jul 24;15(7):e42399. doi: 10.7759/cureus.42399. eCollection 2023 Jul.
9
Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.免疫检查点抑制剂和抗血管生成药物联合治疗对非小细胞肺癌患者骨转移的影响。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2241310. doi: 10.1080/21645515.2023.2241310.
10
Survival benefit of resection surgery for lung adenocarcinoma with bone metastases and a post-operative prognosis nomogram establishment and validation.骨转移肺腺癌切除手术的生存获益及术后预后列线图的建立与验证
J Thorac Dis. 2022 Dec;14(12):4877-4893. doi: 10.21037/jtd-22-1514.